15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Corcept Therapeutics Incorporated, 4 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $50.00 to $135.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $88.00 sits 7% below the current $94.23. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.25 next quarter toward $3.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold00%
Sell120%
Strong Sell00%
Based on 5 analysts giving stock ratings to Corcept Therapeutics Incorporated.
As of Jul, 4 of 5 firms rate CORT a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
CORT EPS & revenue forecast
EPS · NEXT QUARTER
$0.25
Range $0.14 – $0.34 · 3 analysts · +58% YoY
Next period, 3 analysts expect Corcept Therapeutics Incorporated to earn $0.25 a share (range $0.14 – $0.34), versus $0.16 a year earlier. Full-year consensus is $0.56, growing to $3.21 the year after.
REVENUE · NEXT QUARTER
$274.3M
Range $268.0M – $278.0M · 3 analysts · +32% YoY
Revenue is expected to reach $274.3M (range $268.0M – $278.0M), +32.1% year-over-year. Full-year consensus is $1.0B, rising to $1.5B next year.
Top analysts covering Corcept Therapeutics Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CORT.
#1
David Amsellem
Piper Sandler · Rank #95
Buy
$88.00-6.6% to target
Overall win rate
50%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$95.00+0.8% to target
Overall win rate
37%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity
Buy
$135.00+43.3% to target
Coverage
—
+ Follow
#4
KP
Kalpit Patel
Wolfe Research
Sell
$50.00-46.9% to target
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$72.00-23.6% to target
Coverage
—
+ Follow
CORT stock forecast FAQ
What is CORT's average 12-month price target?+
The 5 analysts with a live target average $88.00 for Corcept Therapeutics Incorporated over the next 12 months, ranging from a $135.00 high to a $50.00 low.
Is CORT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for CORT?+
The Street-high target is $135.00 (Canaccord Genuity), and the Street-low is $50.00 (Wolfe Research). The average of all 5 active targets is $88.00.
How many Wall Street analysts cover CORT?+
5 analysts have an active rating on Corcept Therapeutics Incorporated, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CORT?+
Among analysts who currently cover CORT, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Buy with a $88.00 target.
What is Corcept Therapeutics Incorporated's projected EPS for next quarter?+
The consensus estimate is $0.25 per share (range $0.14 – $0.34) across 3 analysts. Full-year EPS is projected at $0.56, rising to $3.21 the following year.
How much revenue is Corcept Therapeutics Incorporated expected to report next quarter?+
Consensus revenue is $274.3M (range $268.0M – $278.0M). Full-year revenue is projected at $1.0B, growing to $1.5B next year.
Have analysts been upgrading or downgrading CORT lately?+
As of Jul, 4 of 5 firms rate CORT a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CORT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
